Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

EDWARD KIMBROUGH

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1699756619
CMS profile
76467
Location
COLUMBIA, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$2,843.68

153 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,804.06 151
Education $39.62 2

By paying entity

PY2024 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 153 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

EDWARD KIMBROUGH

NPI 1699756619 · CMS profile ID 76467

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

COLUMBIA, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 153 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1699756619?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
EDWARD KIMBROUGH, NPI 1699756619, CMS profile ID 76467. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 153 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1699756619?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). EDWARD KIMBROUGH, NPI 1699756619, CMS profile ID 76467. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 153 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1699756619?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
EDWARD KIMBROUGH, NPI 1699756619, CMS profile ID 76467, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 153 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1699756619?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

153 matching records · $2,843.68 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 153 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 153.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Intercept Pharmaceuticals, Inc. $16.9605/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1113633136 CMS
Ardelyx, Inc. $18.5205/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146689658 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $16.9205/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153692266 CMS
ABBVIE INC. $20.2105/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104076318 CMS
PFIZER INC. $13.2105/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131427507 CMS
ABBVIE INC. $14.6504/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104076316 CMS
QOL Medical, LLC $37.9504/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147722832 CMS
Celgene Corporation $14.3104/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101090309 CMS
Gilead Sciences, Inc. $15.5604/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133778686 CMS
Takeda Pharmaceuticals U.S.A., Inc. $11.4004/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137602674 CMS
PFIZER INC. $14.9604/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131351887 CMS
ABBVIE INC. $14.7603/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104076314 CMS
QOL Medical, LLC $32.5403/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147722830 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $15.4803/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153702303 CMS
ABBVIE INC. $11.4903/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104076312 CMS
Lilly USA, LLC $19.4803/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1134966111 CMS
ABBVIE INC. $18.2603/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104076310 CMS
Phathom Pharmaceuticals, Inc. $14.9503/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151082239 CMS
Fresenius Kabi USA, LLC $25.8003/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146948289 CMS
Gilead Sciences, Inc. $18.5303/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133778684 CMS
Merck Sharp & Dohme LLC $16.6103/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141576579 CMS
ABBVIE INC. $16.1203/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104076308 CMS
Takeda Pharmaceuticals U.S.A., Inc. $18.1603/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137602671 CMS
PFIZER INC. $17.7103/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131212413 CMS
ABBVIE INC. $25.0403/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104076306 CMS
Intercept Pharmaceuticals, Inc. $13.2803/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1113633134 CMS
GENZYME CORPORATION $18.9703/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139611356 CMS
QOL Medical, LLC $21.7202/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147722828 CMS
Celgene Corporation $13.8302/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101090305 CMS
Takeda Pharmaceuticals U.S.A., Inc. $16.1402/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137602667 CMS
ABBVIE INC. $19.3802/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104076304 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $15.4502/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153524223 CMS
ABBVIE INC. $16.1602/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104076302 CMS
ABBVIE INC. $8.0502/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104076300 CMS
AIMMUNE THERAPEUTICS, INC. $17.2202/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147018698 CMS
ABBVIE INC. $13.4102/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104076298 CMS
Takeda Pharmaceuticals U.S.A., Inc. $13.7802/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137602663 CMS
ABBVIE INC. $4.7602/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104076296 CMS
ABBVIE INC. $17.5602/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104076294 CMS
ABBVIE INC. $15.8301/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104076292 CMS
Lilly USA, LLC $16.7101/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136154282 CMS
Takeda Pharmaceuticals U.S.A., Inc. $20.7801/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137602659 CMS
PFIZER INC. $10.8101/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131245306 CMS
ABBVIE INC. $17.4501/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104076288 CMS
ABBVIE INC. $2.8701/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104076290 CMS
Ardelyx, Inc. $23.4901/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146689656 CMS
ABBVIE INC. $104.0001/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104076286 CMS
IRONWOOD PHARMACEUTICALS, INC $14.0901/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153766334 CMS
ABBVIE INC. $15.9101/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104076284 CMS
AIMMUNE THERAPEUTICS, INC. $18.0001/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147018654 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,330.91 77
PY2020 $1,320.66 89
PY2021 $2,821.67 192
PY2022 $2,461.95 147
PY2023 $2,462.18 144
PY2024 $2,843.68 153
PY2025 $2,590.15 145

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $346,840.70 119
PY2024 Principal investigator $279,483.78 34
PY2023 Principal investigator $388,075.00 25

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

119 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $12,161.00 12/17/2025 Non-covered Recipient Entity
COLUMBIA DIGESTIVE HEALTH RESEARCH LLC
Study of DONQ52 in Active Celiac Disease No dispute reported 06/30/2026 1211590105
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $2,793.00 12/17/2025 Non-covered Recipient Entity
COLUMBIA DIGESTIVE HEALTH RESEARCH LLC
Study of DONQ52 in Active Celiac Disease No dispute reported 06/30/2026 1211590110
Principal investigator 1 Boehringer Ingelheim International GmbH $1,200.00 12/12/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760945
Principal investigator 1 Boehringer Ingelheim International GmbH $2,500.00 12/12/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760947
Principal investigator 1 Madrigal Pharmaceuticals $2,152.61 12/11/2025 Non-covered Recipient Entity
COLUMBIA DIGESTIVE HEALTH RESEARCH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248254052
Principal investigator 1 Boehringer Ingelheim International GmbH $2,500.00 11/27/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220761005
Principal investigator 1 Boehringer Ingelheim International GmbH $543.18 11/27/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220761011
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 11/19/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220761021
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 11/19/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220761023
Principal investigator 1 Boehringer Ingelheim International GmbH $3,550.80 11/17/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220761003
Principal investigator 1 Boehringer Ingelheim International GmbH $1,561.32 11/17/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220761007
Principal investigator 1 Boehringer Ingelheim International GmbH $3,550.80 11/17/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220761009
Principal investigator 1 Boehringer Ingelheim International GmbH $660.00 11/17/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220761015
Principal investigator 1 Boehringer Ingelheim International GmbH $1,200.00 11/12/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220761013
Principal investigator 1 Boehringer Ingelheim International GmbH $3,566.64 11/06/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760935
Principal investigator 1 Boehringer Ingelheim International GmbH $4,226.64 11/06/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760937
Principal investigator 1 Boehringer Ingelheim International GmbH $660.00 11/06/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760939
Principal investigator 1 Boehringer Ingelheim International GmbH $660.00 11/06/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760941
Principal investigator 1 Boehringer Ingelheim International GmbH $3,566.64 11/06/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760943
Principal investigator 1 Boehringer Ingelheim International GmbH $4,898.52 10/29/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760909
Principal investigator 1 Boehringer Ingelheim International GmbH $3,839.88 10/29/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760911
Principal investigator 1 Boehringer Ingelheim International GmbH $3,839.88 10/29/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760915
Principal investigator 1 Boehringer Ingelheim International GmbH $3,839.88 10/29/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760917
Principal investigator 1 Boehringer Ingelheim International GmbH $1,200.00 10/29/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760919
Principal investigator 1 Boehringer Ingelheim International GmbH $4,898.52 10/29/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760923
Principal investigator 1 Boehringer Ingelheim International GmbH $3,839.88 10/29/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760925
Principal investigator 1 Boehringer Ingelheim International GmbH $3,839.88 10/29/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760927
Principal investigator 1 Boehringer Ingelheim International GmbH $4,898.52 10/29/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760931
Principal investigator 1 Madrigal Pharmaceuticals $1,748.84 10/29/2025 Non-covered Recipient Entity
COLUMBIA DIGESTIVE HEALTH RESEARCH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248252218
Principal investigator 1 Boehringer Ingelheim International GmbH $34.98 10/27/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760949
Principal investigator 1 Boehringer Ingelheim International GmbH $219.78 10/27/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760951
Principal investigator 1 Boehringer Ingelheim International GmbH $803.00 10/27/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760953
Principal investigator 1 Boehringer Ingelheim International GmbH $3.00 10/27/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760955
Principal investigator 1 Boehringer Ingelheim International GmbH $543.18 10/27/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760997
Principal investigator 1 Boehringer Ingelheim International GmbH $2,814.24 10/27/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760999
Principal investigator 1 Boehringer Ingelheim International GmbH $4,077.48 10/27/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220761001
Principal investigator 1 Boehringer Ingelheim International GmbH $99.90 10/27/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220761017
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 10/27/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220761019
Principal investigator 1 Boehringer Ingelheim International GmbH $3,566.64 10/24/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760913
Principal investigator 1 Boehringer Ingelheim International GmbH $660.00 10/24/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760921
Principal investigator 1 Boehringer Ingelheim International GmbH $4,045.80 10/24/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760929
Principal investigator 1 Madrigal Pharmaceuticals $750.00 10/23/2025 Non-covered Recipient Entity
COLUMBIA DIGESTIVE HEALTH RESEARCH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248252006
Principal investigator 1 Genentech, Inc. $53,580.00 10/10/2025 Non-covered Recipient Entity
COLUMBIA DIGESTIVE HEALTH RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211590142
Principal investigator 1 Boehringer Ingelheim International GmbH $195.00 10/03/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760933
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 09/30/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760901
Principal investigator 1 Boehringer Ingelheim International GmbH $124.00 09/30/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760903
Principal investigator 1 Boehringer Ingelheim International GmbH $49.00 09/30/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760905
Principal investigator 1 Boehringer Ingelheim International GmbH $72.00 09/30/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760907
Principal investigator 1 Boehringer Ingelheim International GmbH $3,905.88 09/29/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760991
Principal investigator 1 Boehringer Ingelheim International GmbH $200.00 09/29/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760993
Principal investigator 1 Boehringer Ingelheim International GmbH $46.64 09/24/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760971
Principal investigator 1 Boehringer Ingelheim International GmbH $179.82 09/24/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760973
Principal investigator 1 Boehringer Ingelheim International GmbH $584.00 09/24/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760975
Principal investigator 1 Boehringer Ingelheim International GmbH $403.52 09/24/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760977
Principal investigator 1 Boehringer Ingelheim International GmbH $3.00 09/24/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760979
Principal investigator 1 Boehringer Ingelheim International GmbH $200.00 09/17/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760889
Principal investigator 1 Boehringer Ingelheim International GmbH $624.36 09/17/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760891
Principal investigator 1 Boehringer Ingelheim International GmbH $660.00 09/17/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760893
Principal investigator 1 Boehringer Ingelheim International GmbH $266.64 09/17/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760895
Principal investigator 1 Boehringer Ingelheim International GmbH $7,260.00 09/17/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760899
Principal investigator 1 Boehringer Ingelheim International GmbH $200.00 09/15/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760981
Principal investigator 1 Boehringer Ingelheim International GmbH $624.36 09/15/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760983
Principal investigator 1 Boehringer Ingelheim International GmbH $594.00 09/15/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760985
Principal investigator 1 Boehringer Ingelheim International GmbH $75.00 09/15/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760987
Principal investigator 1 Boehringer Ingelheim International GmbH $660.00 09/15/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760989
Principal investigator 1 Boehringer Ingelheim International GmbH $7,260.00 09/15/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760995
Principal investigator 1 Boehringer Ingelheim International GmbH $660.00 09/03/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760897
Principal investigator 1 Boehringer Ingelheim International GmbH $511.00 08/26/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760887
Principal investigator 1 Boehringer Ingelheim International GmbH $258.48 08/01/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760877
Principal investigator 1 Madrigal Pharmaceuticals $2,152.61 07/31/2025 Non-covered Recipient Entity
COLUMBIA DIGESTIVE HEALTH RESEARCH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248247970
Principal investigator 1 Boehringer Ingelheim International GmbH $660.00 07/30/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760873
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 07/28/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760883
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 07/28/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760885
Principal investigator 1 Boehringer Ingelheim International GmbH $660.00 07/23/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760871
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 07/01/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760875
Principal investigator 1 Boehringer Ingelheim International GmbH $9,011.00 06/24/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760855
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 06/24/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760869
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 06/24/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760967
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 06/24/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760969
Principal investigator 1 Genentech, Inc. $40,521.00 06/13/2025 Non-covered Recipient Entity
COLUMBIA DIGESTIVE HEALTH RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211590131
Principal investigator 1 Madrigal Pharmaceuticals $3,878.86 06/12/2025 Non-covered Recipient Entity
COLUMBIA DIGESTIVE HEALTH RESEARCH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248245501
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 06/01/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760881
Principal investigator 1 Genentech, Inc. $750.00 05/21/2025 Non-covered Recipient Entity
COLUMBIA DIGESTIVE HEALTH RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211590127
Principal investigator 1 Boehringer Ingelheim International GmbH $220.20 05/12/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760857
Principal investigator 1 Boehringer Ingelheim International GmbH $660.00 05/12/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760859
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 05/01/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760861
Principal investigator 1 Boehringer Ingelheim International GmbH $69.96 04/23/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760863
Principal investigator 1 Boehringer Ingelheim International GmbH $657.00 04/23/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760865
Principal investigator 1 Boehringer Ingelheim International GmbH $3.00 04/23/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760867
Principal investigator 1 Boehringer Ingelheim International GmbH $104.94 04/23/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760961
Principal investigator 1 Boehringer Ingelheim International GmbH $620.50 04/23/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760963
Principal investigator 1 Boehringer Ingelheim International GmbH $4.00 04/23/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760965
Principal investigator 1 Genentech, Inc. $38,443.00 04/02/2025 Non-covered Recipient Entity
COLUMBIA DIGESTIVE HEALTH RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211590134
Principal investigator 1 Genentech, Inc. $1,039.00 04/02/2025 Non-covered Recipient Entity
COLUMBIA DIGESTIVE HEALTH RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211590138
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 04/01/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760847
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 04/01/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760851
Principal investigator 1 Boehringer Ingelheim International GmbH $58.00 04/01/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760853
Principal investigator 1 Genentech, Inc. $1,039.00 03/26/2025 Non-covered Recipient Entity
COLUMBIA DIGESTIVE HEALTH RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211590123
Principal investigator 1 Boehringer Ingelheim International GmbH $328.50 03/25/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760843
Principal investigator 1 Boehringer Ingelheim International GmbH $3.00 03/25/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760845
Principal investigator 1 Boehringer Ingelheim International GmbH $328.50 03/25/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760957
Principal investigator 1 Boehringer Ingelheim International GmbH $3.00 03/25/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220760959
Principal investigator 1 Madrigal Pharmaceuticals $3,054.00 03/13/2025 Non-covered Recipient Entity
COLOMBIA DIGESTIVE HEALTH RESEARCH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248240890
Principal investigator 1 Madrigal Pharmaceuticals $16,205.02 03/06/2025 Non-covered Recipient Entity
COLOMBIA DIGESTIVE HEALTH RESEARCH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248240287
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 03/01/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760849
Principal investigator 1 Genentech, Inc. $1,039.00 02/21/2025 Non-covered Recipient Entity
COLUMBIA DIGESTIVE HEALTH RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211590119
Principal investigator 1 Boehringer Ingelheim International GmbH $2.14 02/13/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760829
Principal investigator 1 Boehringer Ingelheim International GmbH $239.89 02/13/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760831
Principal investigator 1 Boehringer Ingelheim International GmbH $5.52 02/13/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760833
Principal investigator 1 Boehringer Ingelheim International GmbH $4.50 02/13/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760835
Principal investigator 1 Boehringer Ingelheim International GmbH $4.50 02/13/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760837
Principal investigator 1 Boehringer Ingelheim International GmbH $21.43 02/13/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760839
Principal investigator 1 Boehringer Ingelheim International GmbH $3.37 02/13/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760841
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 02/01/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760879
Principal investigator 1 Genentech, Inc. $13,507.00 01/13/2025 Non-covered Recipient Entity
COLUMBIA DIGESTIVE HEALTH RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211590115
Principal investigator 1 Madrigal Pharmaceuticals $12,961.59 01/09/2025 Non-covered Recipient Entity
COLOMBIA DIGESTIVE HEALTH RESEARCH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248238338
Principal investigator 1 Madrigal Pharmaceuticals $14,390.00 01/09/2025 Non-covered Recipient Entity
COLOMBIA DIGESTIVE HEALTH RESEARCH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248238341
Principal investigator 1 Madrigal Pharmaceuticals $2,184.60 01/09/2025 Non-covered Recipient Entity
COLOMBIA DIGESTIVE HEALTH RESEARCH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248238345
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 01/01/2025 Non-covered Recipient Entity
Columbia Digestive Health Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220760827